Evidence map›Paper›PMID 32077107›Full record

ArticlePhotochemistry and photobiology2020

Bucillamine Inhibits UVB-Induced MAPK Activation and Apoptosis in Human HaCaT Keratinocytes and SKH-1 Hairless Mouse Skin.

Adil Anwar, Hiba Anwar, Takeshi Yamauchi, Ryan Tseng, Rajesh Agarwal, Lawrence D Horwitz, Zili Zhai, Mayumi Fujita

Open access · greenAbstract read
In one paragraph

Article in Photochemistry and photobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Oral intake of bucillamine, carvedilol, metformin, or phenformin does not protect against UVR-induced squamous cell carcinomas in hairless mice.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024
    Article
  5. Article
  6. Review
  7. Potential Use of Amla (Antioxidants (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Adil AnwarDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Hiba AnwarDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Takeshi YamauchiDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Ryan TsengDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Rajesh AgarwalDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO.
Lawrence D HorwitzDivision of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Zili ZhaiDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0001-5164-3696
Mayumi FujitaDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO.
University of Colorado Anschutz Medical Campus · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Transgenic and Gene Targeting CoreP30AR057212 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI NORRIS, DAVID A. · 2009 to 2018
$6.2M
Modulation of Inflammasome-mediated cytokine activation by EGCG in human melanomaR01CA197919 · NCI · UNIVERSITY OF COLORADO DENVER · PI FUJITA, MAYUMI · 2016 to 2020
$1.9M
Autoinflammation in Human MelanomaI01BX001228 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI FUJITA, MAYUMI · 2012 to 2022
–
BLRD VA I01 BX001228NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA197919NIAMS NIH HHS P30 AR057212NIH/NCI R01 CA197919Veterans Affairs Merit Review Awards 5I01BX001228
6 · The paper itself

Abstract

Ultraviolet B (UVB) radiation is known as a culprit in skin carcinogenesis. We have previously reported that bucillamine (N-[2-mercapto-2-methylpropionyl]-L-cysteine), a cysteine derivative with antioxidant and anti-inflammatory capacity, protects against UVB-induced p53 activation and inflammatory responses in mouse skin. Since MAPK signaling pathways regulate p53 expression and activation, here we determined bucillamine effect on UVB-mediated MAPK activation in vitro using human skin keratinocyte cell line HaCaT and in vivo using SKH-1 hairless mouse skin. A single low dose of UVB (30 mJ cm

Indexed as

Ultraviolet RaysAnimalsAnti-Inflammatory Agents, Non-SteroidalApoptosisCell LineCell ProliferationCysteineEnzyme ActivationFemaleHumansKeratinocytesMiceMice, HairlessMitogen-Activated Protein KinasesSignal TransductionSkinAnti-Inflammatory Agents, Non-SteroidalbucillamineCysteineMitogen-Activated Protein Kinases

Identifiers

PMID32077107
PMCPMC7387142
OpenAlexW3007999302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.